Table 2 p values from the Spearman correlation of proteins measured by targeted mass spectrometry and clinical PD assessment scores in PD subjects and healthy controls (phase I)

From: Plasma proteomics identify biomarkers predicting Parkinson’s disease up to 7 years before symptom onset

 

MMSE

Hoehn-Yahr

UPDRS I

UPDRS II

UPDRS III

UPDRS total score

MMSE

  

4.0E-2

(−0.23)

    

3.0E-3

(−0.31)

5.3E-3

(−0.29)

Hoehn-Yahr

   

1.0E-13

(−0.61)

1.3E-42

(−0.88)

8.1E-19

(−0.69)

7.1E-26

(−0.77)

UPDRS I

  

5.2E-14

(−0.61)

  

2.7E-19

(−0.7)

8.1E-7

(−0.44)

7.6E-13

(−0.59)

UPDRS II

  

1.3E-42

(−0.88)

8.2E-19

(−0.7)

  

1.3E-15

(−0.64)

9.6E-27

(−0.78)

UPDRS III

1.6E-2

(−0.31)

5.4E-19

(−0.69)

1.1E-6

(−0.44)

9.6E-16

(−0.64)

  

2.0E-77

(−0.97)

UPDRS total score

2.1E-2

(−0.29)

1.1E-25

(−0.77)

1.0E-12

(−0.59)

9.6E-27

(−0.78)

2.0E-77

(−0.97)

  

A2M

1.2E-2

(−0.32)

      

8.1E-7

(−0.44)

6.7E-5

(−0.37)

ADIPOQ

  

6.8E-5

(−0.37)

2.4E-2

(−0.25)

9.4E-6

(−0.4)

2.0E-4

(−0.34)

5.5E-5

(−0.37)

C3

9.8E-3

(−0.35)

1.7E-3

(−0.3)

  

3.2E-3

(−0.28)

2.0E-4

(−0.34)

2.6E-4

(−0.34)

CST3

        

2.6E-3

(−0.28)

5.0E-3

(−0.26)

DKK3

  

5.3E-4

(−0.32)

3.8E-2

(−0.24)

3.2E-5

(−0.38)

2.8E-5

(−0.38)

1.5E-5

(−0.4)

FABP5

1.2E-2

(−0.32)

      

1.9E-2

(−0.22)

4.0E-2

(−0.19)

GRN

  

4.8E-7

(−0.45)

  

3.8E-7

(−0.45)

2.8E-8

(−0.49)

3.3E-8

(−0.48)

HPX

4.6E-2

(−0.25)

5.3E-4

(−0.32)

  

2.2E-4

(−0.34)

2.1E-4

(−0.34)

9.2E-5

(−0.36)

HSPA1L

  

4.5E-2

(−0.19)

  

4.6E-2

(−0.2)

2.3E-3

(−0.28)

2.7E-3

(−0.28)

HSPA5

  

3.0E-2

(−0.21)

  

4.6E-2

(−0.2)

1.2E-3

(−0.3)

2.2E-3

(−0.29)

ITIH2

  

3.2E-2

(−0.21)

        

MASP2

  

3.0E-2

(−0.21)

  

1.1E-2

(−0.25)

1.9E-2

(−0.22)

3.1E-2

(−0.2)

PGK1

        

5.6E-3

(−0.25)

1.0E-2

(−0.24)

PPP3CB

  

3.4E-4

(−0.34)

  

3.1E-6

(−0.42)

2.6E-3

(−0.28)

5.3E-4

(−0.32)

PRG4

3.1E-2

(−0.27)

          

PTGDS

3.2E-2

(−0.26)

4.0E-2

(−0.2)

    

2.6E-3

(−0.28)

8.3E-3

(−0.24)

SELE

  

1.3E-2

(−0.24)

4.7E-2

(−0.23)

1.3E-4

(−0.35)

1.4E-3

(−0.3)

5.1E-4

(−0.32)

SERPINA3

3.2E-2

(−0.26)

3.8E-4

(−0.33)

  

7.9E-4

(−0.31)

1.5E-4

(−0.35)

1.4E-4

(−0.35)

SERPINF2

3.1E-2

(−0.27)

3.4E-4

(−0.34)

  

3.8E-4

(−0.33)

1.2E-3

(−0.3)

1.1E-3

(−0.3)

SERPING1

 

7.5E-03

(−0.26)

  

4.6E-02

(−0.2)

2.0E-3

(−0.29)

4.6E-3

(−0.26)

SPP2

  

3.0E-2

(−0.21)

    

3.7E-2

(−0.19)

4.7E-2

(−0.19)

TUBA4A

      

4.6E-2

(−0.2)

1.7E-2

(−0.22)

1.6E-2

(−0.22)

VCAM1

        

8.0E-4

(−0.31)

3.0E-3

(−0.28)

  1. The correlation significance was determined by the Student’s two-tailed t-test. The p values were adjusted for multiple comparisons using the Benjamini–Hochberg procedure with alpha = 0.05. The p values are followed by correlation coefficients in parenthesis.
  2. MMSE mini-mental state examination, UPDRS unified Parkinson’s disease rating scale.
Back to article page